Company Summary - Vernalis PLC (LSE:VER)
84.00p
1.50p
(1.79%)
FTSE Fledgling Pharmaceuticals & BiotechnologyMarket cap: £50.533m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
The group is a development stage pharmaceutical company with significant expertise both in de novo structure and fragment-based drug discovery and pre-clinical and clinical development
| Financials - Interim (6/8/2009) | ||
|---|---|---|
| Turnover | £m | 5.68 |
| Pre-tax Profit | £m | -6.23 |
| EPS | p | -19.50 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Dr. Peter Fellner | Chairman |
| Ian Garland | Chief Executive |
| David Mackney | Finance Director |
Products Brands & Subsidiaries
Products & Brands
Chk1; FAAH; Hsp90 INHIB; NVPAUY922; V10153; V1512; V158866; V2006 (BIIB014); V24343; V3381; V85546; frovatriptan
Subsidiaries
Vernalis Development Ltd; Vernalis (R&D) Ltd; Vernalis (Canada) Inc; Cita NeuroPharmaceuticals Inc
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Second Price Monitoring Extn | 06/10/2009 |
| Price Monitoring Extension | 06/10/2009 |
| Initiates Pilot Study of V3381 in Ch... | 06/10/2009 |